
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc has shown a promising trajectory with a significant ~28% increase in stock value following the announcement of Medicare coverage and pricing for its proprietary NeXT Personal MRD test, particularly in breast cancer. The company has strategically managed its cash burn and margins in Q3 while positioning for accelerated growth in volumes, particularly through its partnership with Tempus, which is expected to enhance marketing efforts for Personalis's tests. Furthermore, the successful reimbursement in breast cancer is anticipated to catalyze earlier positive reimbursement decisions for immuno-oncology monitoring in other cancer indications, leading to upward adjustments in sales estimates for 2026 and beyond.
Bears say
Personalis Inc. has lowered its revenue guidance for 2025 to $68-$73 million, a decrease from previous expectations of $70-$80 million, primarily due to a slowdown in biopharma revenue linked to logistical issues and delays in reimbursement for clinical tests. The firm is facing challenges in accurately forecasting sample flow from its biopharma clients, which adds uncertainty to its revenue potential. Additionally, there are concerns regarding ongoing losses and debt on the balance sheet, indicating that maintaining profitability may be an ongoing struggle for the company.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares